Affordable Access

deepdyve-link
Publisher Website

Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.

Authors
  • Wang, Jing1
  • Liu, Xi-Fang1
  • Feng, Chong2
  • Bao, Quan3
  • Fu, Hong-Ran4
  • 1 Department of Physical Diagnosis, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, China. , (China)
  • 2 Department of Ultrasound, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, China. , (China)
  • 3 Department of Nuclear Magnetic Resonance, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, China. , (China)
  • 4 Department of Clinical Laboratory, The Affiliated Hongqi Hospital of Mudanjiang Medical University, Mudanjiang, China. , (China)
Type
Published Article
Journal
International journal of psychiatry in clinical practice
Publication Date
Nov 01, 2019
Volume
23
Issue
4
Pages
245–250
Identifiers
DOI: 10.1080/13651501.2017.1397700
PMID: 29113521
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Objective: This study aimed to evaluate the efficacy and adverse events of vortioxetine for Chinese patients with major depressive disorder (MDD) over 10 weeks.Methods: A total of 120 patients with MDD were randomly assigned to two groups that received vortioxetine 20 mg or placebo for 10 weeks. The outcomes were the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impressions-Improvement (CGI-I) scale, Sheehan Disability Scale (SDS) at Week 10, and the presence of adverse events.Results: A total of 113 patients completed the study. Vortioxetine showed greater efficacy than the placebo in improving MADRS, HAM-A, CGI-I, and SDS scores at Week 10. However, no significant differences were found between the groups for any treatment-emergent adverse events. No suicide related to vortioxetine treatment was recorded.Conclusions: In summary, the results of this study showed that 10 weeks of vortioxetine treatment was efficacious and well-tolerated in patients with MDD.

Report this publication

Statistics

Seen <100 times